K
Kuniko Matsuda
Researcher at Nippon Medical School
Publications - 47
Citations - 1423
Kuniko Matsuda is an academic researcher from Nippon Medical School. The author has contributed to research in topics: Lung cancer & Idiopathic pulmonary fibrosis. The author has an hindex of 18, co-authored 43 publications receiving 1235 citations. Previous affiliations of Kuniko Matsuda include University of Tsukuba.
Papers
More filters
Journal ArticleDOI
MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
Kazuhiro Kitamura,Masahiro Seike,Tetsuya Okano,Kuniko Matsuda,Akihiko Miyanaga,Hideaki Mizutani,Rintaro Noro,Yuji Minegishi,Kaoru Kubota,Akihiko Gemma +9 more
TL;DR: This study demonstrated that the miR-134/487b/655 cluster contributed to the TGF-β1–induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2, in which suppression subsequently caused loss of PTEN stability in lung cancer cells.
Journal ArticleDOI
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Yutaka Kokubo,Akihiko Gemma,Rintaro Noro,Masahiro Seike,Kiyoko Kataoka,Kuniko Matsuda,Tetsuya Okano,Yuji Minegishi,Akinobu Yoshimura,Masahiko Shibuya,Shouji Kudoh +10 more
TL;DR: The data suggests that the EGFR gene mutation may be possibly lost in some cancer cells with other additional mechanisms for activating Akt, and reintroduction of PTEN or pharmacological downregulation of the constitutive PI3K–Akt-pathway activity may be an attractive therapeutic strategy in cancers with gefitinib resistance.
Journal ArticleDOI
Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
Minoru Inomata,Koichiro Kamio,Arata Azuma,Kuniko Matsuda,Nariaki Kokuho,Yukiko Miura,Hiroki Hayashi,Takahito Nei,Kazue Fujita,Yoshinobu Saito,Akihiko Gemma +10 more
TL;DR: Pirfenidone significantly ameliorated bleomycin-induced pulmonary fibrosis as assessed with quantitative histology and collagen measurement, and fibrocyte inhibition is considered a mechanism of anti-fibrotic action of pirfenid one.
Journal ArticleDOI
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Akihiko Miyanaga,Akihiko Gemma,Rintaro Noro,Kiyoko Kataoka,Kuniko Matsuda,Michiya Nara,Tetsuya Okano,Masahiro Seike,Akinobu Yoshimura,Akiko Kawakami,Haruka Uesaka,Hiroki Nakae,Shoji Kudoh +12 more
TL;DR: The results suggested that HDAC inhibitors may be promising anticancer drugs to NSCLC and the nine-gene classifier is useful in predicting drug sensitivity to HDAC inhibitor treatment and may contribute to achieving individualized therapy for NS CLC patients.
Journal ArticleDOI
EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-β signaling in lung fibroblasts
Ying-Ji Li,Arata Azuma,Jiro Usuki,Shinji Abe,Kuniko Matsuda,Toshiaki Sunazuka,Takako Shimizu,Yukiyo Hirata,Hirofumi Inagaki,Tomoyuki Kawada,Satoru Takahashi,Shoji Kudoh,Satoshi Omura +12 more
TL;DR: Findings suggest that EM703 improves bleomycin-induced pulmonary fibrosis in mice by actions of anti-inflammation and regulation of TGF-β signaling in lung fibroblasts.